Vaxart Inc (VXRT)

7.190
-0.610(-7.82%)
After Hours
7.250
+0.060(+0.834%)
- Real-time Data
  • Volume:
    8,987,159
  • Bid/Ask:
    7.220/7.250
  • Day's Range:
    7.130 - 7.960

VXRT Overview

Prev. Close
7.8
Day's Range
7.13-7.96
Revenue
1.66M
Open
7.78
52 wk Range
3.5-24.84
EPS
-0.46
Volume
8,987,159
Market Cap
879.11M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
12,793,934
P/E Ratio
-
Beta
0.32
1-Year Change
-27.52%
Shares Outstanding
122,268,453
Next Earnings Date
17 Nov 2021
What is your sentiment on Vaxart Inc?
or
Market is currently closed. Voting is open during market hours.

Vaxart Inc News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellSellSell
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellBuy
SummaryStrong SellStrong SellStrong SellStrong SellNeutral

Vaxart Inc Company Profile

Vaxart Inc Company Profile

Employees
28

Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which completed Phase I clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. Vaxart, Inc. has a research collaboration agreement with Janssen Vaccines & Prevention B.V. (Janssen) to evaluate the company’s proprietary oral vaccine platform for the Janssen universal influenza vaccine program. The company is headquartered in South San Francisco, California.

Read More
  • Kindred Biosciences [KIN] - Last Close: $6.34 Kindred Biosciences just agreed to be acquired in a multimillion-dollar deal.Elanco Animal Health (ELAN) will buy all outstanding shares of KIN for $9.25 per share in a deal worth $440 million. Elanco says it will fund the acquisition with pre-payable debt, and the deal is expected to add roughly $100 million to Elanco's innovation revenue expectations by 2025. Closing is slotted for sometime in the third quarter. KIN is up 45.1% on active trading volume on the buyout news.
    0
    • sorry l am confused what has all this got to do with Vaxart?
      0
    • James OlojoKindred has a contract to manufacture Vaxart vaccines
      0
  • Who is ready to flight wihy Vaxart!💪🏻
    0
    • Galin BoshnakovVaxart is a very promising action, its VAAST patent is the only one in the world and will revolutionize the market, my goal is once again the historical highs and if the manipulation continues it will touch 30-32 $
      0
    • What’s your avg. cost
      0
    • 0
  • Hopefully this drops below 7$, then I can buy.
    1
    • hello guys is it a good time to buy ?
      1
      • buy
        0
    • hello guys is it a good time to buy ?
      1
      • hello guys is it a good time to buy ?
        0
        • Likely will SKYROCKET monday with good news from update on covid oral vaccinw
          0
          • what's happening with vaxart???
            0
            • up or down
              0
              • buy the dip.
                1
                • Something big is in pip line
                  0
                  • This company is giving pain
                    0
                    • I wonder about future . projections?
                      0
                      • Why drops 50% today?
                        0
                        • Big dump. partly because vaccine is not as effective as anticipated. buy more now though
                          0
                      • When is good time to buy
                        0
                        • Today
                          0
                      • can anyone told what is this company
                        0
                        • This is a good start this will go up to 21 by end of this week
                          1
                          • Base on what ?
                            0
                        • Hey guys is it too late to buy?
                          0
                          • just buy and hold for 1 week it will be doubled or may be trippled mark my words
                            0
                        • buy as much as you can, this is a hold option
                          0
                          • any reason for so?
                            0
                        • time to buy
                          0
                          • When does vaxart give earning report?
                            0
                            • Today
                              0
                          Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                          Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.